Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2007
05/10/2007WO2006130775A3 Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
05/10/2007WO2006128058A3 Thyromimetics for the treatment of fatty liver diseases
05/10/2007WO2006128056A3 Novel phosphinic acid-containing thyromimetics
05/10/2007WO2006125810A3 Composition for slowing down the development of alzheimer's disease
05/10/2007WO2006122828A3 Optimized injection formulation for rna
05/10/2007WO2006121865A3 Methods of treating recurrent aphthous stomatitis
05/10/2007WO2006120573A3 Heterocyclic n-oxides as hypoxic selective protein kinase inhibitors
05/10/2007WO2006120525A3 Processes for the preparation of nelfinavir and new crystalline form of nelfinavir mesylate
05/10/2007WO2006120472A3 Novel beta-steroid compounds
05/10/2007WO2006118607A3 Hcv inhibitors with carbazole structure
05/10/2007WO2006116716A3 Materials and methods for enhanced degradation of mutant proteins associated with human disease
05/10/2007WO2006113875A3 2 - pyrrolidone derivatives and their uses for the treatment of inflammatory conditions and pain
05/10/2007WO2006112716A3 Nutritional supplement for hiv patients
05/10/2007WO2006105313A3 Compositions of and methods of using oversulfated glycosaminoglycans
05/10/2007WO2006105167A3 Methods, compositions, and formulations for preventing or reducing adverse effects in a patient
05/10/2007WO2006105081A3 Pharmacokinetically improved compounds
05/10/2007WO2006095016A3 Anti-proliferative combination therapy comprising satraplatin or jm118 and a taxane
05/10/2007WO2006090167A3 Hydrazinomethyl, hydr zonomethyl and 5-membered heterocylic compounds which act as mtor inhibitors and their use as anti cancer agents
05/10/2007WO2006088903A3 Pyrazole compounds
05/10/2007WO2006086633A3 Substituted fused [1,2]imidazo[4,5-c] ring compounds and methods
05/10/2007WO2006086510A3 Synthetic sealants
05/10/2007WO2006069363A3 Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3-benzazepine hydrochloride
05/10/2007WO2006067310A3 Use of a dihydroim1dazopyrazine derivative for treating or preventing pain
05/10/2007WO2006063113A3 Ureas as factor xa inhibitors
05/10/2007WO2006045298A3 Treatment of the consequences of alcohol abuse hepatitis pancreatitis
05/10/2007WO2006044290A8 Biosynthesis of philoroglucinol and preparation of 1,3-dihydroxybenzene therefrom
05/10/2007WO2006016178A8 Enantioselective process
05/10/2007WO2005110437A3 Implantable biostructure comprising an osteoconductive member and an osteoinductive material
05/10/2007WO2005102410A3 A system with a reservoir for perfusion management
05/10/2007WO2005102408A3 A telescoping perfusion management system
05/10/2007WO2005069750A3 Therapeutic composition with nanoscale activation agents
05/10/2007WO2005058290A3 Vitamin e for facilitating the synchronization of circadian rhythm
05/10/2007WO2005041855A3 Pharmaceutical formulation containing an ltb4 antagonist, method for the production thereof, and use thereof
05/10/2007WO2005037278A3 Tbenazpril and amlodipine for reducing cardiovascular morbidity
05/10/2007WO2004082637A3 Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor
05/10/2007WO2004064539A3 Fat substitutes
05/10/2007US20070107081 Generating cyclyzed triterpenes in soybean for treatment and prevention of high blood cholesterol and heart disease
05/10/2007US20070106095 Vitamin d receptor modulators
05/10/2007US20070106094 Process For Preparing 4-Pentafluorosulfanylbenzoylguanidines
05/10/2007US20070106087 Therapeutic Malonic Acid/Acetic Acid C60 Tri-Adducts of Buckminsterfullerene and Methods Related Thereto
05/10/2007US20070106077 Synthesis of substituted heterocyclic compounds
05/10/2007US20070106076 Anti-obesity 1,2,3,4,10,10a-hexahydropyrazino [1,2-a] indoles
05/10/2007US20070106072 7a-Furyl or thienyl-substituted steroid compounds
05/10/2007US20070105961 1-Amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
05/10/2007US20070105960 Treatment of learning disabilities and motor skills disorder with norepinephrine reuptake inhibitors
05/10/2007US20070105959 Cynnamyl alcohol derivative compounds and drugs containing the compounds as active ingredient
05/10/2007US20070105958 Compounds for the treatment of metabolic disorders
05/10/2007US20070105957 Dietary Control of Arachidonic Acid Metabolism
05/10/2007US20070105956 Drug containing (2r)-2-propyloctanoic acid as the active ingredient
05/10/2007US20070105955 Compounds for the treatment of metabolic disorders
05/10/2007US20070105954 Formulation containing a carboxylic acid or an ester thereof
05/10/2007US20070105953 Pharmaceutical gallium compositions and methods
05/10/2007US20070105952 Pharmaceutical composition having a ruthenium oxalato compound and method of using the same
05/10/2007US20070105951 non-secosteroidal, phenyl-furan compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1 alpha ,25dihydroxy vitamin D3; useful for treating bone disease and psoriasis
05/10/2007US20070105950 Treatment of ophthalmic disorders using urea and urea derivatives
05/10/2007US20070105949 Intermediates for the preparation of lipoxin A4 analogs
05/10/2007US20070105948 Therapeutic or preventive agents for ischemic neuropathy
05/10/2007US20070105947 External preparation for skin
05/10/2007US20070105946 Tocopherol derivatives with a long hydroxylated chain, which can be used as neurotrophics
05/10/2007US20070105945 may be administered to a patient parenterally and or orally; acts against drug-resistant malaria
05/10/2007US20070105944 Taxane metabolites
05/10/2007US20070105943 Novel antifungal agent containing heterocyclic compound
05/10/2007US20070105942 Supplemental dietary composition for turning on anabolic switches in muscle, stimulating and/or optimizing protein synthesis, and/or potently signaling muscle building and/or growth via molecular pathways
05/10/2007US20070105941 Substituted cyclohexylcarboxylic acid amide compounds
05/10/2007US20070105940 Method for treating pain
05/10/2007US20070105939 Mesylate salt of 5-(2-dimethylaminoethoxy)-1H-indole-2-carboxylic acid [3-(4-hydroxycarbamoylphenyl)prop-2-ynyl]amide
05/10/2007US20070105938 Products and Methods for In Vivo Secretion of Monatin
05/10/2007US20070105937 Indole-3-propionamide and derivatives thereof
05/10/2007US20070105936 new crystals forms of Sodium trans-4-[1-[2,5-dichloro-4-[(1-methyl-1H-3-indolylcarbonyl)amino]phenylacetyl]-(4S)-methoxy(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylate pentahydrate; VLA-4 (very late antigen-4) inhibitor; therapeutic drug for disorders caused by cell adhesion; water soluble, stability
05/10/2007US20070105935 Reacting 2-hydroxymethyl-n-protected-4-substituted pyrrolidine with arylsulfonyl chloride or an optionally substituted alkylsulfonyl chloride in the presence of a base; reacting with p-hydroxybenzenecarboxylic acid derivative (ethyl 4-(N-benzyloxycarbonyl-(4S)-methoxy-(2S)-pyrrolidinylmethoxy)benzoate)
05/10/2007US20070105934 (-)-S isomer of 2,8-dimethyl-3-methylene-1-oxa-8-azaspiro[4.5]decane or salt thereof (YM-796) and carrier, use to accelerate tear and salivary fluid secretion without accompanying sweating; sustained release form
05/10/2007US20070105933 Amino alcohol compounds
05/10/2007US20070105932 2H-or 3H-benzo[e]indazol-1-yl carbamate derivatives, the preparation and therapeutic use thereof
05/10/2007US20070105931 Methods and compositions for inhibiting the proliferation of prostate cancer cells
05/10/2007US20070105930 Methyl 4-[(3-methyl-4-methylsufonyl-2-{[4-(trifluoromethoxy)-phenyl]imino}-6-(trifluoromethyl)-2,3-dihydro-1H-benzimidazol-1-yl)methyl]benzoate; glucagon receptor antagonists; type 2 diabetes mellitus
05/10/2007US20070105929 2, 4, 5 - Trisubstituted Imidazoles And Their Use As Anti-Microbial Agents
05/10/2007US20070105928 6-Pentafluorophenyl-triazolopyrimidines, method for their production and their use for combating pathogenic fungi, in addition to agents containing said substances
05/10/2007US20070105927 Amorphous rizatriptan benzoate
05/10/2007US20070105926 Tetrazoyloxime derivative and agricultural chemical containing the same as active ingredient
05/10/2007US20070105925 Methods for achieving a protective ACE2 expression level to treat kidney disease and hypertension
05/10/2007US20070105924 Vigabatrin bioisoteres and related methods of use
05/10/2007US20070105923 Substantially pure olmesartan medoxomil and processes for its preparation
05/10/2007US20070105922 High affinity and selectivity for GABA A alpha 5 receptor binding sites ; cognitive enhancer; Alzheimer's disease; benzofuran-2-yl-[3-(4-bromo-phenyl)-5-methyl-isoxazol-4-yl]-methanone
05/10/2007US20070105921 Process for Preparing Oxazole Intermediates
05/10/2007US20070105920 2-(Benzimidazol-1-Yl)-N-(4-phenylthiazol-2-yl) acetamide derivatives
05/10/2007US20070105919 Thiazole derivatives
05/10/2007US20070105918 Use of Pramipexole to Treat Amyotrophic Lateral Sclerosis
05/10/2007US20070105917 distinctly folded, amide bond is replaced by aromatic ring (1,2,3,-triazole) yet the chiral main chain and amino acid side chains are maintained; used as peptide mimics; diverse set of side chains without the limitations imposed by secondary amide bond; drug discovery; enzyme inhibitors; HIV protease
05/10/2007US20070105916 Amphiphilic pyridinium compounds, method of making and use thereof
05/10/2007US20070105914 Substituted sulfonamides
05/10/2007US20070105913 Alkynyl aryl carboxamides
05/10/2007US20070105912 Pharmaceutical compositions comprising lercanidipine
05/10/2007US20070105911 Agent for inhibition of cytokine production and agent for inhibition of cell adhesion
05/10/2007US20070105910 Medicinal composition
05/10/2007US20070105909 Compounds useful in therapy
05/10/2007US20070105908 Thiazolimine compound and oxazolimine compound
05/10/2007US20070105907 Novel IDO inhibitors and methods of use thereof
05/10/2007US20070105906 N-(1-{3-[(R)-2-[3-(phenylsulphonylamino)-phenyl]-2-hydroxy-ethylamino]-3-methyl-butyl}-1H-indol-5-yl)-2-cyano-acetamide, used for treating non-insulin dependent diabetes, obesity or overactive bladder
05/10/2007US20070105905 Novel macrocycles for the treatment of cancer
05/10/2007US20070105904 3-(3-(4-(pyridin-2-yloxymethyl)-benzyl)-isoxazol-5-yl)-pyridin-2-ylamine; inhibiting fungal GPI biosynthesis thereby inhibiting expression of cell wall proteins and blocking cell wall assembly while preventing the fungus from attaching to cells